These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 29596687)

  • 1. Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients.
    Sato S; Masui K; Nishina N; Kawaguchi Y; Kawakami A; Tamura M; Ikeda K; Nunokawa T; Tanino Y; Asakawa K; Kaneko Y; Gono T; Ukichi T; Kaieda S; Naniwa T; Kuwana M;
    Rheumatology (Oxford); 2018 Jul; 57(7):1212-1221. PubMed ID: 29596687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
    Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics of cancer-associated myositis complicated by interstitial lung disease: a large-scale multicentre cohort study.
    Kaneko Y; Nunokawa T; Taniguchi Y; Yamaguchi Y; Gono T; Masui K; Kawakami A; Kawaguchi Y; Sato S; Kuwana M;
    Rheumatology (Oxford); 2020 Jan; 59(1):112-119. PubMed ID: 31382295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors for long-term outcome in polymyositis/dermatomyositis-associated interstitial lung diseases.
    Fujisawa T; Hozumi H; Kono M; Enomoto N; Nakamura Y; Inui N; Nakashima R; Imura Y; Mimori T; Suda T
    Respir Investig; 2017 Mar; 55(2):130-137. PubMed ID: 28274528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis.
    Moghadam-Kia S; Oddis CV; Sato S; Kuwana M; Aggarwal R
    Arthritis Care Res (Hoboken); 2016 May; 68(5):689-94. PubMed ID: 26414240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality Risk Stratification Using Cluster Analysis in Patients With Myositis-Associated Interstitial Lung Disease Receiving Initial Triple-Combination Therapy.
    Gono T; Masui K; Sato S; Kuwana M
    Front Med (Lausanne); 2022; 9():883699. PubMed ID: 35615085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?
    Lega JC; Cottin V; Fabien N; Thivolet-Béjui F; Cordier JF
    J Rheumatol; 2010 May; 37(5):1000-9. PubMed ID: 20231208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study.
    Ikeda S; Arita M; Misaki K; Mishima S; Takaiwa T; Nishiyama A; Ito A; Furuta K; Yokoyama T; Tokioka F; Noyama M; Yoshioka H; Ishida T
    Springerplus; 2015; 4():240. PubMed ID: 26101728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan.
    Yamasaki Y; Yamada H; Ohkubo M; Yamasaki M; Azuma K; Ogawa H; Mizushima M; Ozaki S
    J Rheumatol; 2011 Aug; 38(8):1636-43. PubMed ID: 21572147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease.
    Gono T; Masui K; Nishina N; Kawaguchi Y; Kawakami A; Ikeda K; Kirino Y; Sugiyama Y; Tanino Y; Nunokawa T; Kaneko Y; Sato S; Asakawa K; Ukichi T; Kaieda S; Naniwa T; Okano Y; Kuwana M;
    Arthritis Rheumatol; 2021 Apr; 73(4):677-686. PubMed ID: 33118321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].
    Xie MM; Zou RY; Li Y; Liu Y; Chen LL; Liu XQ; Zhao Q; Ding JJ; Chen ZY; Cai HR
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct; 42(10):765-770. PubMed ID: 31594111
    [No Abstract]   [Full Text] [Related]  

  • 13. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study.
    Ye S; Chen XX; Lu XY; Wu MF; Deng Y; Huang WQ; Guo Q; Yang CD; Gu YY; Bao CD; Chen SL
    Clin Rheumatol; 2007 Oct; 26(10):1647-54. PubMed ID: 17308858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease.
    Johnson C; Pinal-Fernandez I; Parikh R; Paik J; Albayda J; Mammen AL; Christopher-Stine L; Danoff S
    Lung; 2016 Oct; 194(5):733-7. PubMed ID: 27166633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia.
    Yura H; Sakamoto N; Satoh M; Ishimoto H; Hanaka T; Ito C; Hasegawa T; Tanaka S; Miyamura T; Nakashima S; Hara A; Kakugawa T; Oda K; Kido T; Obase Y; Ishimatsu Y; Yatera K; Kawakami A; Mukae H
    Respir Med; 2017 Nov; 132():189-194. PubMed ID: 29229096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Idiopathic inflammatory myopathies from the viewpoint of rheumatologists].
    Gono T; Katsumata Y; Kawaguchi Y
    Brain Nerve; 2013 Nov; 65(11):1275-82. PubMed ID: 24200605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study.
    Ji SY; Zeng FQ; Guo Q; Tan GZ; Tang HF; Luo YJ; Tang ZQ; Han YF
    Chin Med J (Engl); 2010 Mar; 123(5):517-22. PubMed ID: 20367973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics of dermatomyosits/polymyositis associated interstitial lung disease according to the autoantibody.
    Kishaba T; McGill R; Nei Y; Ibuki S; Momose M; Nishiyama K; Nagano H; Yamashiro S
    J Med Invest; 2018; 65(3.4):251-257. PubMed ID: 30282869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
    Enomoto Y; Suzuki Y; Hozumi H; Mori K; Kono M; Karayama M; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inui N; Suzuki D; Ogawa N; Nakashima R; Mimori T; Iwashita T; Suda T
    Arthritis Res Ther; 2017 Jan; 19(1):9. PubMed ID: 28103926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of HRCT in myositis-associated interstitial lung disease.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Aihara K; Ikezoe K; Watanabe K; Taguchi Y; Hatta K; Oga T; Chin K; Nagai S; Mimori T; Mishima M
    Respir Med; 2013 May; 107(5):745-52. PubMed ID: 23485097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.